Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice

Area of Science:

• Cardiology
• Diabetology
• Pharmacology

Background:

• Individuals with diabetes mellitus have a substantially elevated risk of cardiovascular (CV) disease.
• Traditional CV risk factors like hyperlipidemia, hypertension, and a prothrombotic state exacerbate this risk.
• Despite glucose control and risk factor management, CV events persist due to atherosclerosis complexity, necessitating novel therapeutic strategies.

Purpose of the Study:

• To evaluate the efficacy of novel risk factors in predicting cardiovascular events in diabetic patients.
• To explore new therapeutic approaches for reducing cardiovascular risk in diabetes.
• To assess the impact of adding ramipril to existing regimens on cardiovascular outcomes in high-risk diabetic patients.

Main Methods:

• Analysis of cardiovascular risk factors in diabetic populations.
• Review of clinical trial data for novel risk factors.
• Evaluation of data from the Heart Outcomes Prevention Evaluation (HOPE) trial.

Main Results:

• Existing risk factor management does not eliminate cardiovascular events in diabetes.
• Novel risk factors like C-reactive protein and endothelial dysfunction are proposed but lack clinical trial data.
• The HOPE trial demonstrated that adding ramipril, an ACE inhibitor, to standard treatment reduced CV risk in high-risk diabetic patients.

Conclusions:

• Current management strategies are insufficient to fully mitigate cardiovascular risk in diabetes.
• New therapeutic avenues are required to address the high burden of CV disease in this population.
• Ramipril shows promise as an adjunct therapy for reducing cardiovascular events in high-risk diabetic individuals.